Fosun Pharma In-licenses Innovative TB Treatment

Fosun Pharma has entered a collaboration that gives the company exclusive China rights to PaMZ, a novel TB drug regimen developed by the TB Alliance. In exchange for the rights, Fosun will sponsor the China cohort of a global Phase III of PaMZ, and it has agreed to produce the drugs at a reasonable cost. The regimen is designed to treat both drug-sensitive TB and multi-drug resistant TB. More details.... Stock Symbols: (SHA: 600196; HK: 2196) Share this with colleagues: // //